Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...

Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Silence Therapeutics in a report issued on ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

H.C. Wainwright raised the firm’s price target on Neuphoria Therapeutics (NEUP) to $21 from $8 and keeps a Buy rating on the shares. The firm ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

XOMA (NASDAQ:XOMA – Free Report) had its price objective trimmed by HC Wainwright from $123.00 to $104.00 in a report published on Monday morning,Benzinga reports. The firm currently has a buy rating ...

H.C. Wainwright raised the firm’s price target on BlackSky (BKSY) to $20 from $12 and keeps a Buy rating on the shares. The firm says that as ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Knightscope (NasdaqCM:KSCP) with a Buy recommendation. As of January 28, 2025, the average one-year price target ...